Canaccord Genuity Downgrades NuVasive (NUVA) to Hold; Pricing Pressure in The Spine Disorder Business
Tweet Send to a Friend
Canaccord Genuity downgrades NuVasive (Nasdaq: NUVA) from Buy to Hold. PT lowered from $52 to $36.
Canaccord analyst says, “Since ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, “Since ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
